OBJECTIVE: To evaluate the efficacy and @entity137 of topotecan-based combined chemotherapy for refractory or relapsed @entity1583 . METHODS: Twenty-one @entity1 with refractory or relapsed @entity3052 ( @entity3052 ), @entity1893 ( @entity1893 ) or high risk @entity2590 ( @entity2590 ) were treated by @entity1945 with @entity2592 , @entity5257 or @entity786 . All @entity1 received a single course as salvage therapy. RESULTS: The overall response rate of one course was 61.9% with 9/21 (42.9%) CR and 4/21 (19%) PR. Severe myelosuppression was observed in all @entity1 . Agranulocytic time was 12.6 days in @entity3052 and 7.5 days in @entity1893 . Sixteen of 21 @entity1 received G-CSF 300 micro g/d All @entity1 received supportive treatment of transfusion. Fever and documented infection developed in 15 @entity1 . @entity1503 was mild. CONCLUSION: Topotecan-based combined chemotherapy has significant antitumour activity and acceptable @entity137 as salvage therapy for high risk @entity1583 .

[Topotecan-based combined chemotherapy for refractory or relapsed XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5257 :: ('MESH:D000677', 'Chemical') :: ['amsacrine'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['AL', 'acute leukemia'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Non-hematologic toxicity'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancies'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']
@entity1583 :: (MESH:D019337,Disease) :: ['hematologic malignancies']
